Pharma says government must act quickly to safeguard generic drugs supply


Pharmaceutical industry leaders have warned the government needs to be “fleet of foot” to avoid a significant cost if a no-deal Brexit disrupts approval of generic and biosimilar medicines.

You need to be signed in to read more


Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All of and our HSJ mobile app
  • News and insight on all areas of public funded healthcare
  • Expert commentary, insight and analysis from industry leaders
  • 9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics

Sign into your account here